| 000 | 01308 a2200373 4500 | ||
|---|---|---|---|
| 005 | 20250513200224.0 | ||
| 264 | 0 | _c20000111 | |
| 008 | 200001s 0 0 eng d | ||
| 022 | _a0114-5916 | ||
| 024 | 7 |
_a10.2165/00002018-199921001-00011 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRoberts, D J | |
| 245 | 0 | 0 |
_aAssessing the cardiac safety of ebastine. Epilogue. _h[electronic resource] |
| 260 |
_bDrug safety _c1999 |
||
| 300 |
_a89-92 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aButyrophenones _xadverse effects |
| 650 | 0 | 4 | _aCation Transport Proteins |
| 650 | 0 | 4 | _aDNA-Binding Proteins |
| 650 | 0 | 4 | _aERG1 Potassium Channel |
| 650 | 0 | 4 | _aEther-A-Go-Go Potassium Channels |
| 650 | 0 | 4 |
_aHistamine H1 Antagonists _xadverse effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aPiperidines _xadverse effects |
| 650 | 0 | 4 | _aPotassium Channel Blockers |
| 650 | 0 | 4 | _aPotassium Channels |
| 650 | 0 | 4 | _aPotassium Channels, Voltage-Gated |
| 650 | 0 | 4 |
_aTorsades de Pointes _xchemically induced |
| 650 | 0 | 4 | _aTrans-Activators |
| 650 | 0 | 4 | _aTranscriptional Regulator ERG |
| 773 | 0 |
_tDrug safety _gvol. 21 Suppl 1 _gp. 89-92 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2165/00002018-199921001-00011 _zAvailable from publisher's website |
| 999 |
_c10553943 _d10553943 |
||